CA2174236A1 - Superoxide dismutase and mimetics thereof - Google Patents
Superoxide dismutase and mimetics thereofInfo
- Publication number
- CA2174236A1 CA2174236A1 CA002174236A CA2174236A CA2174236A1 CA 2174236 A1 CA2174236 A1 CA 2174236A1 CA 002174236 A CA002174236 A CA 002174236A CA 2174236 A CA2174236 A CA 2174236A CA 2174236 A1 CA2174236 A1 CA 2174236A1
- Authority
- CA
- Canada
- Prior art keywords
- mimetics
- superoxide dismutase
- relates
- radicals
- modulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
- A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating intra- and extracellular levels of superoxide radicals and thereby processes in which such radicals are a participant.
The invention also relates to compounds and compositions suitable for use in such methods.
The invention also relates to compounds and compositions suitable for use in such methods.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002614621A CA2614621A1 (en) | 1993-10-15 | 1994-10-13 | Superoxide dismutase and mimetics thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13620793A | 1993-10-15 | 1993-10-15 | |
US136,207 | 1993-10-15 | ||
PCT/US1994/011558 WO1995010185A1 (en) | 1993-10-15 | 1994-10-13 | Superoxide dismutase and mimetics thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002614621A Division CA2614621A1 (en) | 1993-10-15 | 1994-10-13 | Superoxide dismutase and mimetics thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2174236A1 true CA2174236A1 (en) | 1995-04-20 |
CA2174236C CA2174236C (en) | 2008-02-12 |
Family
ID=22471830
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002174236A Expired - Lifetime CA2174236C (en) | 1993-10-15 | 1994-10-13 | Superoxide dismutase and mimetics thereof |
Country Status (9)
Country | Link |
---|---|
US (1) | US5747026A (en) |
EP (2) | EP0723398B1 (en) |
JP (1) | JPH09505805A (en) |
AT (1) | ATE291351T1 (en) |
AU (1) | AU702596B2 (en) |
CA (1) | CA2174236C (en) |
DE (1) | DE69434313T2 (en) |
ES (1) | ES2237753T3 (en) |
WO (1) | WO1995010185A1 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994339A (en) * | 1993-10-15 | 1999-11-30 | University Of Alabama At Birmingham Research Foundation | Oxidant scavengers |
US6127356A (en) | 1993-10-15 | 2000-10-03 | Duke University | Oxidant scavengers |
US5747026A (en) * | 1993-10-15 | 1998-05-05 | University Of Alabama At Birmingham Research Foundation | Antioxidants |
AU3758695A (en) * | 1994-09-20 | 1996-04-09 | Duke University | Oxidoreductase activity of manganic porphyrins |
EP0831891B1 (en) * | 1995-06-07 | 2005-10-19 | Duke University | Oxidant scavengers |
EP0846003A1 (en) * | 1995-08-17 | 1998-06-10 | Monsanto Company | Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands |
CA2183834C (en) * | 1995-08-22 | 2003-09-09 | Hiroshi Maeda | Antihypertensive agents containing pyrazolopyrimidine derivatives |
CZ271198A3 (en) * | 1996-03-13 | 1999-01-13 | Monsanto Company | Manganese bioconjugates of iron complexes of macrocyclic ligands containing nitrogen, acting as catalysts for superoxide dismutation |
WO1999023097A1 (en) * | 1997-11-03 | 1999-05-14 | Duke University | Substituted porphyrins |
DE69928655T2 (en) | 1998-04-24 | 2006-08-24 | Duke University | SUBSTITUTED PORPHYRINE |
AU5673099A (en) | 1998-08-11 | 2000-03-06 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Inhibitors of amyloid formation |
GB9817845D0 (en) | 1998-08-17 | 1998-10-14 | Glaxo Group Ltd | Chemical compounds |
WO2000023568A2 (en) * | 1998-10-06 | 2000-04-27 | Albert Einstein College Of Medicine Of Yeshiva University | Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells |
US6695830B2 (en) * | 1999-01-15 | 2004-02-24 | Scimed Life Systems, Inc. | Method for delivering medication into an arterial wall for prevention of restenosis |
US6210392B1 (en) * | 1999-01-15 | 2001-04-03 | Interventional Technologies, Inc. | Method for treating a wall of a blood vessel |
AU779283B2 (en) * | 1999-01-25 | 2005-01-13 | Aeolus Sciences, Inc. | Substituted porphyrins |
IT1306716B1 (en) * | 1999-06-21 | 2001-10-02 | Mendes S U R L | ASSOCIATION OF LACTIC BACTERIA AND ITS USE FOR THE PREVENTION AND / OR THERAPEUTIC TREATMENT OF INFECTIONS AND INFLAMMATORY STATES. |
SE9903985D0 (en) * | 1999-11-03 | 1999-11-03 | Aga Ab | Use of nitric oxide |
FR2806911B1 (en) * | 2000-03-28 | 2003-01-10 | Univ Rene Descartes | USE OF SOD MIMETICS IN THE TREATMENT OF HEPATOCELLULAR DEFICIENCIES |
US6403788B1 (en) | 2000-07-11 | 2002-06-11 | Eukarion, Inc. | Non-genotoxic metalloporphyrins as synthetic catalytic scavengers of reactive oxygen species |
WO2002022573A2 (en) * | 2000-09-15 | 2002-03-21 | The Scripps Research Institute | Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
US20020072512A1 (en) * | 2000-12-08 | 2002-06-13 | Metaphore Pharmaceuticals, Inc | Method of preventing and treating HIV-mediated central nervous system damage |
AU2002248366B2 (en) * | 2001-01-19 | 2006-10-26 | Aeolus Sciences, Inc. | Cancer therapy |
EP1353655A2 (en) * | 2001-01-26 | 2003-10-22 | Metaphore Pharmaceuticals Inc. | Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes |
EP1439842A4 (en) * | 2001-06-01 | 2009-09-02 | Nat Jewish Med & Res Center | Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance |
US20040116350A1 (en) * | 2001-09-17 | 2004-06-17 | Paul Wentworth Jr | Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
US20050129680A1 (en) * | 2001-09-17 | 2005-06-16 | Paul Wentworth | Antimicrobial activity of antibodies |
US20040157280A1 (en) * | 2001-09-17 | 2004-08-12 | Paul Wentworth | Antibody mediated ozone generation |
WO2003072053A2 (en) | 2002-02-22 | 2003-09-04 | The Curators Of The University Of Missouri | Compounds for treatment of copper overload |
EP1513537A4 (en) * | 2002-06-07 | 2006-09-06 | Univ Duke | Substituted porphyrins |
WO2004044582A2 (en) * | 2002-11-14 | 2004-05-27 | Novartis Ag | Antibody- or neutrophil-mediated ozone generation |
MXPA05011773A (en) | 2003-05-01 | 2006-02-17 | Cornell Res Foundation Inc | Method and carrier complexes for delivering molecules to cells. |
US7432369B2 (en) | 2004-03-29 | 2008-10-07 | Inotek Pharmaceuticals Corporation | Pyridyl-substituted porphyrin compounds and methods of use thereof |
WO2008018932A2 (en) | 2006-05-01 | 2008-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
EP2300032A4 (en) | 2008-05-13 | 2012-12-05 | Univ Kansas | Metal abstraction peptide (map) tag and associated methods |
US11382895B2 (en) | 2008-05-23 | 2022-07-12 | National Jewish Health | Methods for treating injury associated with exposure to an alkylating species |
JP4891367B2 (en) | 2009-05-21 | 2012-03-07 | トヨタ自動車株式会社 | Solvent composition |
US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
WO2013181461A2 (en) | 2012-06-01 | 2013-12-05 | University Of Kansas | Metal abstraction peptide with superoxide dismutase activity |
CN104190927B (en) | 2014-08-11 | 2016-05-18 | 苏州大学 | A kind of synchronous powder feeding system space laser processing and three-dimensional method and device |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US4758422A (en) * | 1985-01-04 | 1988-07-19 | Salutar Inc. | Ferrioxamine paramagnetic contrast agents for MR imaging |
JPS63500175A (en) * | 1985-05-22 | 1988-01-21 | リポソ−ム テクノロジ−,インコ−ポレイテツド | Liposome inhalation method and inhalation system |
DK402785D0 (en) * | 1985-09-03 | 1985-09-03 | Syn Tek Ab | PROCEDURE FOR THE PREPARATION OF AN ENZYM |
EP0282899B1 (en) * | 1987-03-14 | 1996-01-10 | BOEHRINGER INGELHEIM INTERNATIONAL GmbH | Human manganese superoxide dismutase (hMn-SoD) |
US5223538A (en) * | 1987-03-31 | 1993-06-29 | Duke University | Superoxide dismutase mimic |
US5227405A (en) * | 1987-03-31 | 1993-07-13 | Duke University | Superoxide dismutase mimic |
US5171680A (en) * | 1988-06-14 | 1992-12-15 | Chiron Corporation | Superoxide dismutase analogs having novel binding properties |
DE69027383T2 (en) * | 1989-03-06 | 1996-11-14 | Suntory Ltd | NEW SUPEROXYD DISMUTASE |
DK455789D0 (en) * | 1989-09-15 | 1989-09-15 | Symbicom Ab | POLYPEPTIDE |
EP0424033A3 (en) * | 1989-10-19 | 1991-07-31 | Pola Chemical Industries Inc | External skin preparation |
EP0462836A3 (en) * | 1990-06-20 | 1992-08-26 | Mitsui Toatsu Chemicals, Inc. | Recombinant vector plasmid capable of expressing human manganese superoxide dismutase, and process of producing this enzyme |
US5202317A (en) * | 1990-09-13 | 1993-04-13 | The Regents Of The University Of California | Synthetic drug molecules that mimic metalloenzymes |
US5217966A (en) * | 1990-09-13 | 1993-06-08 | The Regents Of The University Of California | Synthetic drug molecules that mimic metalloenzymes |
AU8947791A (en) * | 1990-11-01 | 1992-05-26 | Scripps Research Institute, The | Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions |
EP0598753B1 (en) * | 1991-07-19 | 1998-03-18 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
US5696109A (en) * | 1992-12-07 | 1997-12-09 | Eukarion, Inc. | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease |
US5747026A (en) * | 1993-10-15 | 1998-05-05 | University Of Alabama At Birmingham Research Foundation | Antioxidants |
WO2000023568A2 (en) * | 1998-10-06 | 2000-04-27 | Albert Einstein College Of Medicine Of Yeshiva University | Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells |
AU779283B2 (en) * | 1999-01-25 | 2005-01-13 | Aeolus Sciences, Inc. | Substituted porphyrins |
US6448239B1 (en) * | 1999-06-03 | 2002-09-10 | Trustees Of Princeton University | Peroxynitrite decomposition catalysts and methods of use thereof |
-
1994
- 1994-02-02 US US08/190,504 patent/US5747026A/en not_active Expired - Lifetime
- 1994-10-13 JP JP7512010A patent/JPH09505805A/en not_active Ceased
- 1994-10-13 DE DE69434313T patent/DE69434313T2/en not_active Expired - Lifetime
- 1994-10-13 ES ES94930729T patent/ES2237753T3/en not_active Expired - Lifetime
- 1994-10-13 AT AT94930729T patent/ATE291351T1/en not_active IP Right Cessation
- 1994-10-13 EP EP94930729A patent/EP0723398B1/en not_active Expired - Lifetime
- 1994-10-13 WO PCT/US1994/011558 patent/WO1995010185A1/en active IP Right Grant
- 1994-10-13 AU AU79763/94A patent/AU702596B2/en not_active Expired
- 1994-10-13 EP EP04010434A patent/EP1442747A1/en not_active Withdrawn
- 1994-10-13 CA CA002174236A patent/CA2174236C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU7976394A (en) | 1995-05-04 |
EP0723398B1 (en) | 2005-03-23 |
WO1995010185A1 (en) | 1995-04-20 |
DE69434313T2 (en) | 2006-03-30 |
ES2237753T3 (en) | 2005-08-01 |
DE69434313D1 (en) | 2005-04-28 |
CA2174236C (en) | 2008-02-12 |
AU702596B2 (en) | 1999-02-25 |
ATE291351T1 (en) | 2005-04-15 |
EP1442747A1 (en) | 2004-08-04 |
EP0723398A4 (en) | 1999-03-24 |
EP0723398A1 (en) | 1996-07-31 |
US5747026A (en) | 1998-05-05 |
JPH09505805A (en) | 1997-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2174236A1 (en) | Superoxide dismutase and mimetics thereof | |
CA2224173A1 (en) | Sunscreen compositions | |
IL135949A0 (en) | Substituted porphyrins | |
CA2172513A1 (en) | Aminocyclohexylesters and uses thereof | |
CA2228752A1 (en) | (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol methanesulfonate trihydrate | |
CA2054590A1 (en) | Novel cyclosporins | |
CA2218090A1 (en) | Cleansing emulsions | |
IL122451A0 (en) | Oxidant scavengers | |
CA2374442A1 (en) | Silicone gel containing salicylic acid | |
BG102425A (en) | (methylsulphonyl)phenyl-2-(5h)-furanons as cyclooxygenase-2-inhibitors | |
HU9503539D0 (en) | Process for the light stabilization of sunscreen agents derived from dibenzoylmethane, light-stabilized cosmetic sunscreen compositions thus obtained, and uses thereof | |
CA2163361A1 (en) | Therapeutic substituted guanidines | |
CA2191507A1 (en) | Polysiloxane-polyoxyethylene-polyoxypropylene triblock copolymers and defoaming compounds containing them | |
CA2102241A1 (en) | Use of macrolide compounds for eye diseases | |
CA2199844A1 (en) | Compositions for the treatment of skin disorders | |
CA2218289A1 (en) | Cd45rb binding compounds for the prevention of transplant rejection | |
WO1996021468A3 (en) | Chemically modified interferon | |
CA2207103A1 (en) | Methods to identify hemochromatosis | |
CA2180846A1 (en) | Method of treating disorders of the eye | |
AU6682594A (en) | Treatment of septic shock | |
FR2742048B1 (en) | USE OF 2-ETHYLHEXYL ALPHA-CYANO-BETA, BETA-DIPHENYLACRYLATE TO IMPROVE THE STABILITY OF COSMETIC COMPOSITIONS CONTAINING P-METHYL-BENZYLIDENE CAMPHOR IN ASSOCIATION WITH A DIBENZOYLMETH DERIVATIVE | |
CA2169694A1 (en) | Substituted benzenesulfonylureas and -thioureas, processes for their preparation, their use as a medicament or diagnostic, and medicament containing them | |
CA2293808A1 (en) | Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases | |
WO1996031208A3 (en) | Use of substituted piperidine or pyrrolidine compounds for treating sigma-receptor modulated disorders | |
CA2353527A1 (en) | Use of neurotrophic factor stimulators for the treatment of ophthalmic neurodegenerative diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20141014 |